IO Essentials: Welcome and History of IO

• Welcome, Christos Georgiades, MD, PhD, Johns Hopkins University
• History of IO, Stephen Solomon, MD, Memorial Sloan Kettering Cancer Center

IO Essentials: Sponsored Content presented by Boston Scientific

IO Essentials: Sponsored Content presented by Varian, a Siemens Healthineers Company

IO Essentials: Sponsored Content presented by NeuWave

IO Essentials: Sponsored Content presented by Penumbra

IO Essentials: Sponsored Content presented by AstraZeneca

IO Essentials: Study Design and Ethics in IO

Moderators: Isabel Gala Newton, MD, PhD, USCS Health and VA San Diego Healthcare System; Rony Avritscher, MD, University of Texas MD Anderson Cancer Center

• Getting Started in IO Research, Lynn Jeanette Savic, MD, Universitätsmedizin Charité Berlin
• Trial Design and Statistical Methods for Medical Research, Nicole Varble, PhD, National Institute of Health
• Ethics and Consent in IO, Isabel Gala Newton, MD, PhD, USCS Health and VA San Diego Healthcare System
• Building A Successful Mentor-Mentee Relationship, Alda Tam, MD, MD Anderson Cancer Center

IO Essentials Welcome Reception: Supported by Penumbra

Join Penumbra at the King's Fish House located at 100 W Broadway. 

Breakfast and Industry Symposium presented by Boston Scientific

Cryoablation for Painful Bone Metastases: From Clinical Studies to FDA Approval to Patient Impact

• Scott Genshaft, MD, UCLA Health
• Rahul Sheth, MD, University of Texas MD Anderson Cancer Center

President's Welcome & Dr. Sidney Wallace and Dr. Michael J. Wallace Distinguished Lecture

• President's Welcome, Muneeb Ahmed, MD, FSIR, Beth Israel Deaconess Medical Center/Harvard Medical School
• Program Chair's Program Overview, Vijay Ramalingam, MD, FSIR, Beth Israel Deaconess Medical Center/Harvard Medical School
• Wallace Lecture Laudation, William Rilling, MD, FSIR, Medical College of Wisconsin
• Dr. Sidney Wallace and Dr. Michael J. Wallace Distinguished Lecture, Prof. Thierry de Baere, MD, Gustave Roussy Cancer Center

State-of-the-Art HCC

Moderators: Laura Crocetti, MD, PhD, EBIR, University of Pisa; Parissa Tabrizian, MD, MSc, FACS, Mount Sinai Medical Center

• Standard of Care Systemic Therapies and Pivotal Trials, Adam Burgoyne, MD, PhD, UC San Diego
• Barcelona Update and BCLC Stage Migration Issues, David C. Madoff, MD, Yale School of Medicine
• 2024 Resection and Transplantation Updates, Parissa Tabrizian, MD, MSc, FACS, Mount Sinai Medical Center
• Current Status: Locoregional Primer, Laura Crocetti, MD, PhD, EBIR, University of Pisa

Expo Hall Open

Lunch and Industry Symposium presented by BD

Novel Power Driven Bone Biopsy Technologies and Techniques for Routine and Complex Procedures

• Jay Acharya, MD, Keck Medicine of USC
• Benjamin Levin, MD, UCLA

Scholars may attend the symposium of their choice.

Lunch and Industry Symposium presented by Boston Scientific

TheraSphere Y90: Revving up "RPM" and Accelerating the Future of Combination Therapy

• Tyler Sandow, MD, Ochsner Health
• Lingling Du, MD, Ochsner Medical Center

Scholars may attend the symposium of their choice.

Ablation Hands-on: Image Guidance & Robotics

Moderators: Bruno C. Odisio, MD, PhD, FSIR, FCIRSE, European Institute of Oncology (IRCCS); Marie Beerman, MD, Danderyd Hospital

• Rationale Behind Using Image Guidance and Advanced Ablation, Denis Szejnfeld, MD, PhD, Unifesp
• Basics of Stereotactic Ablation and Setting Up a Program, Iwan Paolucci, PhD, MD Anderson Cancer Center
• Stereotactic RF Ablation of the Liver: Why I Use It and the Advantages of Multiple Needles, Reto Bale, MD FCIRSE, Medical University Inssbruck
• Stereotactic Microwave Ablation of Liver Lesions, Marie Beerman, MD, Danderyd Hospital
• Putting it All Together: Treatment Planning, Guidance, and Ablation, Bruno C. Odisio, MD, PhD, FSIR, FCIRSE, European Institute of Oncology (IRCCS)
• Hands-on Learning, All above faculty

SIO Grant Showcase

Moderator: Julius Chapiro, MD, PhD, Yale School of Medicine

• SIO Grants Overview, Julius Chapiro, MD, PhD, Yale School of Medicine
• 2022 Grant Update: Single Cell Analysis of Combined Thermal Ablation and Immunotherapy of HCC, Prof. S. Nahum Goldberg, MD, FSIR, FCIRSE, Hadassah Hebrew University Medical Center
• 2022 Grant Update: Stoking an Anti-Liver Cancer Immune Response with Cryoablation Plus Intratumoral Immunostimulant, Isabel Gala Newton, MD, PhD, UCSD Health and VA San Diego Healthcare System
• 2022 Grant Update: Immunobiologic and Metabolic Determinants of Response to Combination Locoregional and Immunotherapy in HCC, Kelley Weinfurtner, MD, University of Pennsylvania
• 2022 Grant Update: Engineered Extracellular Vesicles to Modulate Immunotherapy in Liver Cancer, Kiyoyuki Minamiguchi, MD, PhD, MD Anderson Cancer Center
• 2023 Grant Update: Spatial proteogenomics for prediction of response in combined radioembolization and immunotherapy of HCC, Elif Öcal, MD, LMU University Hospital Munich
• 2023 Grant Update: Understanding the Influence of Hepatocellular Carcinoma Tumor Immune Microenvironment on Response to Y-90 Radioembolization and Potential Combinations with Immune Checkpoint Inhibition, Christopher D. Malone, MD, Mallinckrodt Institute of Radiology at Washington University School of Medicine

Exhibitor Showcase

Scholars - please convene at the front of the exhibit hall at 3:30 for a brief overview of the Exhibitor Showcase and recieve your Exhibit Hall Passport.

HCC Tumor Board

Moderators: Riad Salem, MD, MBA, Northwestern University; Muneeb Ahmed, MD, FSIR, Beth Israel Deaconess Medical Center/Harvard Medical School

Science and Industry Welcome Reception

All attendees are invited to join us to celebrate the start of the 2024 Annual Meeting. This networking reception will include poster and award presentations in the Exhibit Hall.

Breakfast and Industry Symposium presented by TriSalus Life Sciences

Seeking to Enable Immunotherapy for Liver and Pancreatic Tumors: Updates from PERIO Trials

• Intratumoral Pressure: A Barrier to Drug Delivery, Alexander Kim, MD, TriSalus Life Sciences
• Immunosuppression and Novel Treatment Approaches, Steven C. Katz, MD, FACS, TriSalus Life Sciences/Brown University School of Medicine
• The PERIO-01 and -02 Trials: Enabling Immunotherapy for Uveal Melanoma Liver Metastases and Primary Liver Cancers, Rahul Sheth, MD, MD Anderson Cancer Center

Breakfast and CME Session: Synergizing for Success in HCC: Immuotherapy Advances and the Role of the Interventional Radiologist-Oncologist Collaboration Across the Disease Continuum

Presented by Peerview Institute for Medical Education

• Preconsult Prep: Establishing the Alliance in HCC—The Importance of IR/Oncologist Collaboration for Addressing Challenges and Unmet Needs in HCC, Lipika Goyal, MD, Stanford Medicine
• Clinical Consult Session 1:  Partnership at the Initial Stages of Disease: Updates in Immunotherapy and LRT Options in Early- and Intermediate-Stage HCC, Lipika Goyal, MD, Stanford Medicine; Riad Salem, MD, MBA, Northwestern University
• Clinical Consult Session 2:   Coordinating Care at Disease Progression: Ensuring a Smooth Transition When Integrating Systemic Therapy in Advanced-Stage HCC, Lipika Goyal, MD, Stanford Medicine; Riad Salem, MD, MBA, Northwestern University
• Summary and Q&A, Lipika Goyal, MD, Stanford Medicine; Riad Salem, MD, MBA, Northwestern University

IO Essentials: Solid Tumor Interventions

Moderators: Christos Georgiades, MD, PhD, Johns Hopkins University; Nishita Kothary, MD, FSIR, Stanford School of Medicine

• Physics of Ablation Modalities, Christos Georgiades, MD, PhD, Johns Hopkins University
• Liver: Introduction to Ablation and Guidelines Overview, Nishita Kothary, MD, FSIR, Stanford School of Medicine
• Lung: Introduction to Ablation and Guidelines Overview, Stephen Hunt, MTR, MD, PhD, FSIR, University of Pennsylvania
• RCC: Introduction to Ablation and Guidelines Overview, Erica Alexander, MD, Memorial Sloan Kettering Cancer Center
• Radioembolization: Getting Started in Y90, Juan Gimenez, MD, Ochsner Health
• Intro to TACE and Patient Management, Zach Berman, MD, UC San Diego
• Pain Management Techniques and IO, Rahul Sheth, MD, MD Anderson Cancer Center

Scientific Oral Abstracts

Moderators: Nicholas Fidelman, MD, University of California San Francisco; Rony Avrischer, MD, University of Texas MD Anderson Cancer Center

• Four-year overall survival update from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma, Farshid Dayyani, MD, PhD, University of California, Irvine
• Initial efficacy and safety of RP1 plus nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study, Bartosz Chmielowski, MD, University of California Los Angeles
• EMERALD-1: a Phase 3, randomized, placebo-controlled study of transarterial chemoembolization (TACE) combined with durvalumab (D) with or without bevacizumab (B) in participants with unresectable hepatocellular carcinoma (uHCC) eligible for embolization, Joe Erinjeri, MD, PhD, Memorial Sloan Kettering Cancer Center
• Embolic protection and thrombosis risk of inferior vena cava filters in cancer patients: a single center, retrospective study, Koustav Pal, The University of Texas MD Anderson Cancer Center
• Ultrasound-guided thermal ablation of cervical metastases from thyroid carcinoma, Ricardo Miguel Costa de Freitas, MD, PhD, Instituto do Cancer do Estao de Sao Paulo (HCFMUSP)
• Sarcopenia and Myosteatosis are Associated with Worse Survival after TACE of Liver Metastases, Fereshteh Yazdanoanah, MD, HMBA, University of Pennsylvania
• Factors impacting survival after transarterial radioembolization in patients with intrahepatic cholangiocarcinoma: A combined analysis of the prospective CIRT and CIRT-FR studies, Nathalie Kaufmann, MBA, CIRSE

Expo Hall Open

Lunch and Industry Symposium presented by Sirtex Medical

Optimizing Y90 Treatment Logistics with SIR-Spheres Order-Map-Treat and FLEXdose Delivery Programs  

• Robert Grammer, MD, West Virginia University

Scholars may attend the symposium of their choice.

Lunch and Industry Symposium presented by Guerbet

Leveraging the Benefits of Lipiodol Imaging in HCC Management

• Julius Chapiro, MD, PhD, Yale School of Medicine
• Marcelo Guimaraes, MD, MBA, FSIR, Medical University of South Carolina (MUSC)
• Ziga Cizman, MD, MPH, University of Utah

Scholars may attend the symposium of their choice.

Renal/GU

Moderators: David Breen, MD, MRCP, FRCR, University Hospitals Southampton; Rodrigo Gobbo, MD, PhD, Hospital Israelita Albert Einstein

• T1A and Current Guidelines, Rodrigo Gobbo, MD, PhD, Hospital Israelita Albert Einstein
• Surgical Perspectives on Percutaneous Ablation, Pratik Kanabur, MD, UCLA
• Ablation in Patients with Chronic Renal Disease, Christos Georgiades, MD, PhD, Johns Hopkins University
• Central Renal Cancer and Ablation in Difficult Locations, Grant Schmit, MD, Mayo Clinic
• T1B Disease: What is the Current Role of IR? AJ Gunn, MD, University of Alabama at Birmingham

Must-Know Studies for MDT Tumor Board

Moderators: Phillipe Pereira, MD, SLK Kliniken GmbH Heilbronn; Rony Avritscher, MD, University of Texas MD Anderson Cancer Center; Terence P. Gade, MD, PhD, University of Pennsylvania

• The Importance of Trials and Registries in Interventional Oncology, Phillipe Pereira, MD, SLK Kliniken GmbH Heilbronn
• ACCLAIM, Constantinos T. Sofocleous, MD, PhD, FSIR, FCIRSE, Memorial Sloan Kettering Cancer Center
• IMbrave150, Adam Burgoyne, MD, PhD, UC San Diego
• LAUNCH, Lynn Jeanette Savic, MD, Universitätsmedizin Charité Berlin
• Dosisphere, S. Cheenu Kappadath, PhD, FAAPM, University of Texas MD Anderson Cancer Center

mCRC Tumor Board

Moderators: Constantinos T. Sofocleous, MD, PhD, FSIR, FCIRSE, Memorial Sloan Kettering Cancer Center; Martijn Meijerink, MD, PhD, Amsterdam UMC

Faculty: Guy Johnson, MD, PharmD, University of Washington; Yuman Fong, MD, PhD, City of Hope Medical Center; Heather McGee, MD, PhD, City of Hope Medical Group; Kimberly Perez, MD, Dana-Farber Cancer Institute/Harvard Medical School

SIO Trivia Night 2024: Tinseltown Trivia

Join us in the Seaview Ballroom at the Hyatt Regency Long Beach to show off your trivia skills! 

Breakfast and CME Session: Optimal Preparation and Treatment Endpoints in cTACE

Breakfast will be provided. Following the overview, participants will engage in hands-on learning at workstations supervised by expert faculty.

• Overview, Sarah White, MD, MS, Medical College of Wisconsin
• William Rilling, MD, FSIR, Medical College of Wisconsin
• Michael Soulen, MD, University of Pennsylvania
• Nicholas Fidelman, MD, University of California San Francisco
• Terence P. Gade, MD, PhD, University of Pennsylvania
• Nishita Kothary, MD, FSIR, Stanford School of Medicine
• Nadine Abi-Jaoudeh, MD, UC Irvine

IO Essentials: Preparing for Tumor Boards

Moderators: Stephen Hunt, MTR, MD, PhD, FSIR, University of Pennsylvania; Nadine Abi-Jaoudeh, MD, UC Irvine

• BCLC Immunotherapy: Current Status and Outcomes, Cristal Brown, MD, MHS, UT Austin Dell Medical School
• Liver Transplantation: Patient Selection, Anatomy, and Outcomes, Jennifer Berumen, MD, UC San Diego
• Tumor Board, All above faculty; Dimitrios Filippiadis, MD, PhD, MSc, EBIR, University General Hospital Attikon; Nishita Kothary, MD, FSIR, Stanford School of Medicine

Scientific Oral Abstracts

Moderators: Nicholas Fidelman, MD, University of California San Francisco; Rony Avrischer, MD, University of Texas MD Anderson Cancer Center

• Cone-beam Computed Tomography Guided Percutaneous Cryoablation of Bone Metastases due to Endocrine Tumors: A prospective clinical trial, Ricardo Miguel Costa de Freitas, MD, PhD, Instituto do Cancer do Estao de Sao Paulo (HCFMUSP)
• Deep Convolutional-neural-network-based Metal Artifact Reduction for CT-guided Interventional Oncology Procedures (MARIO), Wenchao Cao, Mayo Clinic
• Pharmacokinetic comparison of percutaneously injected ultrasound and x-ray imageable thermosensitive poloxamer-based hydrogel containing doxorubicin versus free drug in swine, Jose F. Delgado, BS, National Institutes of Health
• Heterogeneity of Hepatocellular Carcinoma (HCC) Response to Y-90 Microsphere Treatment Revealed through in vitro Screening of Patient-Derived Tumoroids and Cell Lines, Christopher Malone, MD, Washington University School of Medicine
• Histopathologic Analysis of Time-dependent PD-1/PD-L1 expression after TACE in an Orthotopic HCC Model, Ajay Varadhan, Northwestern Memorial Hospital
• Shapeable temporary hydrodissection gel for thermal protection during liver lesion ablation., Avik Som, MD, PhD, Massachusetts General Hospital
• CT-guided high dose rate brachytherapy can induce multiple systemic proteins of proliferation and angiogenesis predicting outcome in HCC, Lukas Salvermoser, MD, University Hospital Munich Germany

Expo Hall Open

Lunch and Industry Symposium presented by Stryker

Radiofrequency Ablation for Vertebral Turmors

• Jay Acharya, MD, Keck Medicine of USC

Scholars may attend the symposium of their choice.

Lunch and Industry Symposium presented by AstraZeneca

Treatment Option for Unresectable Hepatocellular Carcinoma

• Mohammed Najeeb Al-Hallak, MD, Karmanos Cancer Institute

Scholars may attend the symposium of their choice.

Interventional Oncology and Immunotherapy

Moderators: Prof. S. Nahum Goldberg, MD, FSIR, FCIRSE, Hadassah Hebrew University Medical Center; Terence P. Gade, MD, PhD, University of Pennsylvania

• General Overview: Where Are We Currently? Gosse J. Adema, PhD, Radboud University Medical Center
• Immunotherapy and Percutaneous Ablation: What's New and Where Are We Going? Michal Mauda-Havakuk, MD, PhD, Tel-Aviv Sourasky Medical Center
• Immunotherapy and Intra-Arterial Therapy: What's New and Where Are We Going? Rony Avritscher, MD, University of Texas MD Anderson Cancer Center
• Positive Effects of Local Therapies, Prof. S. Nahum Goldberg, MD, FSIR, FCIRSE, Hadassah Hebrew University Medical Center

Oligomets Tumor Board

Moderators: David Breen, MD, MRCP, FRCR, University Hospitals Southampton; Matthew Callstrom, MD, PhD, Mayo Clinic

Faculty: Alexis Kelekis, MD, PhD, EBIR, National and Kapodistrian University of Athens; Jess Maxwell, MD, MBA, MD Anderson Cancer Center; Ann Radlow, MD, MPH, UCLA Dept. of Radiation Oncology; Sandy Liu, MD, City of Hope